---
title: "US stock night market volatility: Regencell Bioscience rose 4.08% in the night market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250049336.md"
description: "Regencell Bioscience rose 4.08% in the after-hours market; Pfizer fell 1.03%, with a trading volume of USD 396,300; Eli Lilly rose 0.02%, with a trading volume of USD 71,700; Novo Nordisk fell 0.25%, with a trading volume of USD 46,800"
datetime: "2025-07-25T01:01:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250049336.md)
  - [en](https://longbridge.com/en/news/250049336.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250049336.md)
generator: "portal-rs"
---

# US stock night market volatility: Regencell Bioscience rose 4.08% in the night market

**U.S. Stock Night Market Movements**

Regencell Bioscience rose 4.08% in the night market. Based on recent important news:

1.  On June 16, Regencell Bioscience conducted a 38-for-1 stock split, resulting in a very low number of circulating shares, driving the stock price to soar.

2.  On June 17, Regencell Bioscience pre-market rose 45%, with retail investors flocking in.

3.  On June 18, the stock price of Regencell Bioscience skyrocketed, seen as driven by speculation.

**Stocks with High Trading Volume in the Industry**

Pfizer fell 1.03% in the night market, with a trading volume of $396,300. Based on recent important news:

1.  On July 24, Pfizer signed a global exclusive licensing agreement with 3SBio, obtaining the development rights for PD-1/VEGF bispecific antibodies, strengthening its oncology product line, which led to a 1.03% drop in stock price.

2.  On July 24, the FDA announced the cessation of production of Pfizer's Glucotrol XL medication, raising market concerns about its future profitability.

3.  On July 23, analysts maintained a wait-and-see attitude towards Pfizer, believing that five other stocks had better investment value, affecting investor confidence.

Eli Lilly rose 0.02% in the night market, with a trading volume of $71,700. Based on recent important news:

1.  On July 24, Eli Lilly announced that its acquisition deal with Verve would be completed on July 25, which was positively received by the market, pushing the stock price slightly up.

2.  On July 24, Eli Lilly will announce its second-quarter financial report on August 7, and investors are optimistic about the upcoming report, supporting the stock price.

3.  On July 23, analysts maintained a "Moderate Buy" rating on Eli Lilly but noted that there are better investment options, affecting market confidence.

Novo Nordisk fell 0.25% in the night market. Based on recent important news:

1.  On July 22, Novo Nordisk announced that its drug Ozempic® was approved for a new indication in China, which was positively received by the market, but the stock price did not see a significant increase.

2.  On July 23, an Indian pharmaceutical company plans to launch a generic version of Novo Nordisk's weight loss drug, which may affect its market share.

3.  On July 22, the FDA announced that some insulin products from Novo Nordisk would be discontinued, which could impact the company's revenue

### Related Stocks

- [RGC.US](https://longbridge.com/en/quote/RGC.US.md)

## Related News & Research

- [Midnight: v8 upgrade adds private smart contracts and custom tokens - Q4 2026](https://longbridge.com/en/news/300868339.md)
- [Goldpesa Suffers About $114,900 Loss in Attack Linked to GPXHooks Rebalance Flaw](https://longbridge.com/en/news/300869009.md)
- [SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026](https://longbridge.com/en/news/300869024.md)
- [Midnight: Midnight City plans to enable AI agent trading - Q4 2026](https://longbridge.com/en/news/300868349.md)
- [Popular eatery abruptly closes all locations nationwide amid expansion](https://longbridge.com/en/news/300867117.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**